May 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.54 USD | -1.13% | +3.01% | -17.21% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.21% | 87.21B | |
+48.40% | 780B | |
+41.77% | 627B | |
+20.39% | 334B | |
+6.89% | 296B | |
+17.34% | 244B | |
-0.53% | 217B | |
+11.63% | 214B | |
+4.73% | 161B | |
-3.70% | 159B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves expanded use of Bristol's cancer cell therapy